High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
IVIG Effective in Treating Infants with HDFN
A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.
IVIG Plus IVMP Does Not Increase Remission Rates in CIDP Patients
According to a recent study, adding intravenous methylprednisolone to intravenous immune globulin induction therapy does not significantly increase remission rates among patients with chronic inflammatory demyelinating polyradiculoneuropathy.
FDA Grants Breakthrough Designation for Wayrilz to Treat Autoimmune Hemolytic Anemia
The U.S. Food and Drug Administration has granted a designation as breakthrough therapy to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase inhibitor, for the treatment of patients with warm autoimmune hemolytic anemia.
FDA Fast Tracks Gamgertamig for ITP
FDA has granted fast track designation to gamgertamig (OM336) for the treatment of immune thrombocytopenia and cold and warm autoimmune hemolytic anemia.
Study Shows No Causal Relationship Between COVID-19 Vaccination and Myositis
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.
FDA Approves Expanded Label for Jascayd for PPF
Boehringer Ingelheim’s Jascayd (nerandomilast) has been given an expanded label by the U.S. Food and Drug Administration to include use in adults with progressive pulmonary fibrosis.
Lunsumio VELO Has Been Approved for R/R FL
FDA has approved CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
CDC Approves Change to Nation’s Childhood Immunization Schedule
The Centers for Disease Control and Prevention has approved a change to the nation’s childhood immunization schedule to drop the long-standing practice of giving all newborns a hepatitis B vaccine within 24 hours of birth.
FDA Approves VOYXACT to Treat Kidney Disease
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.